Fudan University Cancer Center
Welcome,         Profile    Billing    Logout  
 54 Trials 
35 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shao, Zhimin
NCT05871437: Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer

Recruiting
4
379
RoW
Huaier granule, Z20000109（NMPA Approval Number）
Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Early-stage Breast Cancer
10/24
08/25
NCT05860907: Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis

Not yet recruiting
4
384
RoW
Huaier Granule, Z20000109（NMPA Approval Number）
Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Breast Cancer Stage IV
10/25
10/27
NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Recruiting
4
1072
RoW
Huaier Granule, Z20000109（NMPA Approval Number）
Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
12/27
07/28
NCT03980054: A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Active, not recruiting
3
1192
RoW
Pyrotinib, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
07/22
07/24
NCT04629846: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Completed
3
517
RoW
Trastuzumab, Herceptin®, QL1209, Recombinant anti-HER-2 domain Ⅱ humanized monoclonal antibody injection, Pertuzumab, Perjeta®, Docetaxel, Docetaxel injection, surgery
Qilu Pharmaceutical Co., Ltd.
Breast Cancer
08/22
10/23
NCT04613674: A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Completed
3
441
RoW
Camrelizumab Plus Chemotherapy, placebo+chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Triple Negative Breast Cancer
09/23
03/24
SKB264-Ⅲ-11, NCT06279364: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Recruiting
3
524
RoW
SKB264, Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, Carboplatin
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple Negative Breast Cancer
07/26
07/26
GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Not yet recruiting
3
200
RoW
T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection
Changchun GeneScience Pharmaceutical Co., Ltd.
Breast Cancer Subjects
11/25
03/26
NCT06846437: JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Recruiting
3
228
RoW
JSKN003, Trastuzumab emtansine (T-DM1)
Shanghai JMT-Bio Inc.
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
10/26
12/28
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
NCT05673629: Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer

Recruiting
3
552
RoW
Utidelone Injection in combination with AC, Docetaxel Injection in combination with AC
Beijing Biostar Pharmaceuticals Co., Ltd.
Breast Cancer
06/25
12/25
DYNASTY-Breast02, NCT06018337: A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer

Recruiting
3
532
Europe, Canada, US, RoW
DB-1303/BNT323, Capecitabine, Paclitaxel, Nab-paclitaxel
DualityBio Inc., BioNTech SE
Metastatic Breast Cancer
05/26
07/28
NCT07003074: A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Not yet recruiting
3
642
RoW
TQB2102 for Injection, Docetaxel combined + Trastuzumab +Pertuzumab
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
07/29
07/30
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT06891833: A Study of BL-M07D1 + Pertuzumab With or Without Taxane Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Not yet recruiting
2/3
120
RoW
BL-M07D1, Pertuzumab, Taxane
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
HER2-positive Breast Cancer
12/28
12/28
NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Recruiting
2
120
RoW
Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks）
RemeGen Co., Ltd.
Breast Cancer
12/25
12/26
TQB2102-II-01, NCT06198751: A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Recruiting
2
104
RoW
6.0 mg/kg of TQB2102 for injection, 7.5 mg/kg of TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
01/25
02/26
NCT06516926: SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Not yet recruiting
2
240
RoW
SHR-4602
Jiangsu HengRui Medicine Co., Ltd.
HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
11/25
12/26
Yang, Jin Mo
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction.

Completed
3
765
RoW
TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group
Vigonvita Life Sciences
Erectile Dysfunction
02/23
02/23
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction.

Recruiting
3
472
RoW
TPN171H, Simmerafil
Vigonvita Life Sciences
Erectile Dysfunction
04/25
04/25
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Not yet recruiting
3
400
RoW
JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Breast Cancer
04/25
03/29
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
NCT07003074: A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Not yet recruiting
3
642
RoW
TQB2102 for Injection, Docetaxel combined + Trastuzumab +Pertuzumab
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
07/29
07/30
OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting
2/3
549
Europe, RoW
Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®
Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.
Recurrent or Metastatic Breast Cancer
02/24
12/25
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
2/3
254
RoW
SPH4336 Tablets, SPH4336 Tablets Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Locally Advanced or Metastatic Breast Cancer
12/25
12/25
TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Recruiting
2
42
RoW
TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
06/26
06/28
TQB3616-II-04, NCT06702618: Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Not yet recruiting
2
33
RoW
TQB3616 capsule+Fulvestrant Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
05/26
12/26
NCT06851442: Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Recruiting
1/2
75
RoW
TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
04/27
04/27
TQB2102-Ib-01, NCT06115902: A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Recruiting
1
150
RoW
TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
12/25
12/26
SPEED, NCT06862206: This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Not yet recruiting
N/A
1000
RoW
benralizumab
AstraZeneca
Chronic Obstructive Pulmonary Disease
01/26
01/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shao, Zhimin
NCT05871437: Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer

Recruiting
4
379
RoW
Huaier granule, Z20000109（NMPA Approval Number）
Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Early-stage Breast Cancer
10/24
08/25
NCT05860907: Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis

Not yet recruiting
4
384
RoW
Huaier Granule, Z20000109（NMPA Approval Number）
Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Breast Cancer Stage IV
10/25
10/27
NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Recruiting
4
1072
RoW
Huaier Granule, Z20000109（NMPA Approval Number）
Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
12/27
07/28
NCT03980054: A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Active, not recruiting
3
1192
RoW
Pyrotinib, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
07/22
07/24
NCT04629846: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Completed
3
517
RoW
Trastuzumab, Herceptin®, QL1209, Recombinant anti-HER-2 domain Ⅱ humanized monoclonal antibody injection, Pertuzumab, Perjeta®, Docetaxel, Docetaxel injection, surgery
Qilu Pharmaceutical Co., Ltd.
Breast Cancer
08/22
10/23
NCT04613674: A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Completed
3
441
RoW
Camrelizumab Plus Chemotherapy, placebo+chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Triple Negative Breast Cancer
09/23
03/24
SKB264-Ⅲ-11, NCT06279364: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Recruiting
3
524
RoW
SKB264, Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, Carboplatin
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple Negative Breast Cancer
07/26
07/26
GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Not yet recruiting
3
200
RoW
T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection
Changchun GeneScience Pharmaceutical Co., Ltd.
Breast Cancer Subjects
11/25
03/26
NCT06846437: JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Recruiting
3
228
RoW
JSKN003, Trastuzumab emtansine (T-DM1)
Shanghai JMT-Bio Inc.
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
10/26
12/28
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
NCT05673629: Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer

Recruiting
3
552
RoW
Utidelone Injection in combination with AC, Docetaxel Injection in combination with AC
Beijing Biostar Pharmaceuticals Co., Ltd.
Breast Cancer
06/25
12/25
DYNASTY-Breast02, NCT06018337: A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer

Recruiting
3
532
Europe, Canada, US, RoW
DB-1303/BNT323, Capecitabine, Paclitaxel, Nab-paclitaxel
DualityBio Inc., BioNTech SE
Metastatic Breast Cancer
05/26
07/28
NCT07003074: A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Not yet recruiting
3
642
RoW
TQB2102 for Injection, Docetaxel combined + Trastuzumab +Pertuzumab
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
07/29
07/30
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT06891833: A Study of BL-M07D1 + Pertuzumab With or Without Taxane Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Not yet recruiting
2/3
120
RoW
BL-M07D1, Pertuzumab, Taxane
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
HER2-positive Breast Cancer
12/28
12/28
NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Recruiting
2
120
RoW
Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks）
RemeGen Co., Ltd.
Breast Cancer
12/25
12/26
TQB2102-II-01, NCT06198751: A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Recruiting
2
104
RoW
6.0 mg/kg of TQB2102 for injection, 7.5 mg/kg of TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
01/25
02/26
NCT06516926: SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Not yet recruiting
2
240
RoW
SHR-4602
Jiangsu HengRui Medicine Co., Ltd.
HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
11/25
12/26
Yang, Jin Mo
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction.

Completed
3
765
RoW
TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group
Vigonvita Life Sciences
Erectile Dysfunction
02/23
02/23
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction.

Recruiting
3
472
RoW
TPN171H, Simmerafil
Vigonvita Life Sciences
Erectile Dysfunction
04/25
04/25
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Not yet recruiting
3
400
RoW
JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Breast Cancer
04/25
03/29
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
NCT07003074: A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Not yet recruiting
3
642
RoW
TQB2102 for Injection, Docetaxel combined + Trastuzumab +Pertuzumab
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
07/29
07/30
OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting
2/3
549
Europe, RoW
Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®
Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.
Recurrent or Metastatic Breast Cancer
02/24
12/25
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
2/3
254
RoW
SPH4336 Tablets, SPH4336 Tablets Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Locally Advanced or Metastatic Breast Cancer
12/25
12/25
TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Recruiting
2
42
RoW
TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
06/26
06/28
TQB3616-II-04, NCT06702618: Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Not yet recruiting
2
33
RoW
TQB3616 capsule+Fulvestrant Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
05/26
12/26
NCT06851442: Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Recruiting
1/2
75
RoW
TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
04/27
04/27
TQB2102-Ib-01, NCT06115902: A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Recruiting
1
150
RoW
TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
12/25
12/26
SPEED, NCT06862206: This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Not yet recruiting
N/A
1000
RoW
benralizumab
AstraZeneca
Chronic Obstructive Pulmonary Disease
01/26
01/26

Download Options